Results 261 to 270 of about 7,510,778 (382)

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

Enrichment of differentially expressed gene signatures in Hallmark functional annotation categories.

open access: green, 2016
Roman Kosoy   +15 more
openalex   +2 more sources

Transcriptome assembly and annotation of johnsongrass ( Sorghum halepense ) rhizomes identify candidate rhizome‐specific genes [PDF]

open access: gold, 2018
Nathan Ryder   +7 more
openalex   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

The battle for user-friendly bioinformatics

open access: yesFrontiers in Genetics, 2013
David Roy Smith
doaj   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Biologically-informed killer cell immunoglobulin-like receptor gene annotation tool. [PDF]

open access: yesBioinformatics
Ford MKB   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy